|
A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia.
|
|
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
|
|
Challenges with serum protein electrophoresis in assessing progression and clinical response in patients with Waldenström macroglobulinemia.
|
|
Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia.
|
|
Familial Disease Predisposition Impacts Treatment Outcome in Patients With Waldenström Macroglobulinemia
|
|
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: A preliminary study
|
|
Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia
|
|
microRNA aberrations in Waldenström macroglobulinemia.
|
|
Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma.
|
|
Multiple myeloma, version 1.2013.
|
|
MYD88 L265P Somatic Mutation in Waldenström’s Macroglobulinemia
|
|
Response assessment in Waldenström macroglobulinaemia:Update from the 6th International Workshop on WM
|
|
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013
|
